Advances in Tumor-Infiltrating Lymphocyte (TIL) as a Prognostic Factor and for Treating Invasive Cutaneous Melanoma DOI Open Access
Gabriel Alves Freiria de Oliveira, Daniel Arcuschin de Oliveira, Melissa Yoshimi Sakamoto Maeda Nisimoto

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(23), P. 12596 - 12596

Published: Nov. 23, 2024

Invasive cutaneous melanoma is responsible for about 5% of skin tumors yet liable nearly 70% cancer-related deaths. Despite notable advancements over the past decade, including immunotherapies and targeted treatments, more than half invasive patients ultimately succumb to disease due therapeutic resistance. To overcome this obstacle, strategies such as combining with drugs or adding epigenetic therapies have been investigated. Tumor-infiltrating lymphocytes (TILs) therapy has emerged a promising option whose continues progress despite standard treatments. This article aims introduce TIL review recent outcomes in prognosis its application management.

Language: Английский

Exosome-based immunotherapy as an innovative therapeutic approach in melanoma DOI Creative Commons

Shabnam Babaei,

Manouchehr Fadaee, Hajar Abbasi‐Kenarsari

et al.

Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)

Published: Oct. 31, 2024

The malignant form of melanoma is one the deadliest human cancers that accounts for almost all skin tumor-related fatalities in its later stages. Achieving an exhaustive understanding reliable cancer-specific markers and molecular pathways can provide numerous practical techniques direct way toward development rational curative medicines to increase lifespan patients. Immunotherapy has significantly enhanced treatment metastatic late-stage melanoma, resulting incredible positive responses therapy. Despite increasing occurrence median survival rate patients with advanced, inoperable terminal disease increased from around six months years. current knowledge tumor microenvironment (TME) interaction immune system resulted swift growth innovative immunotherapy treatments. Exosomes are small extracellular vesicles (EVs), ranging 30 150 nm size, majority cells released them. possess natural advantages such as high compatibility living organisms low potential causing reactions, making them delivering therapeutic agents like chemotherapy drugs, nucleic acids, proteins. This review highlights recent advancements using exosomes approach providing medications melanoma.

Language: Английский

Citations

12
Tenascin-C targeting strategies in cancer DOI
Sayda Dhaouadi, Balkiss Bouhaouala‐Zahar, Gertraud Orend

et al.

Matrix Biology, Journal Year: 2024, Volume and Issue: 130, P. 1 - 19

Published: April 18, 2024

Language: Английский

Citations

7
Primary Cutaneous Melanoma—Management in 2024 DOI Open Access
Anthony Dixon, Michael J Sladden, Christos C. Zouboulis

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(6), P. 1607 - 1607

Published: March 11, 2024

Background: Maximizing survival for patients with primary cutaneous melanomas (melanomas) depends on an early diagnosis and appropriate management. Several new drugs have been shown to improve in high-risk melanoma patients. Despite well-documented guidelines, many do not receive optimal management, particularly when considering patient age. Objective: provide update management from the time of decision biopsy a suspicious skin lesion. Methods: We reviewed melanoma-management research published between 2018 2023 identified where such findings impact confirmed melanomas. Pubmed, Google Scholar, Ovid Cochrane Library were used as search tools. Results: 81 publications since 2017 that changed management; 11 2018, 12 2019, 10 2020, 2021, 17 2022 18 2023. Discussion: Delayed or inaccurate is more likely occur partial shave punch obtain histopathology. Wherever feasible, local excision narrow margin should be method choice suspected melanoma. The Breslow thickness remains single most important predictor outcome, followed by age then ulceration. BAUSSS biomarker, (Breslow thickness, Age, Ulceration, Subtype, Sex Site) provides accurate determining mortality risk than older currently employed approaches, including sentinel lymph node biopsy. Patients metastatic and/or nodal disease considered adjuvant drug therapy (ADT). Further, are increasingly ADT, even without spread. Invasive less 1 mm thick usually managed radial mms normal skin. If 2 mm, select 20 mm. When over clinical undertaken. In situ 5 Mohs control surgery. Such wide excisions around given only surgery can regarded therapeutic required. who had one at increased another Ideal ongoing includes regular lifelong checks. Total body photography if has naevi, especially atypical/dysplastic naevi identified. Targeted approaches occupational lifestyle exposure ultraviolet light important. Management also needs include consideration vitamin D supplementary therapy.

Language: Английский

Citations

6
ALDH2 is a novel biomarker and exerts an inhibitory effect on melanoma DOI Creative Commons
Lei Hua,

Jinfeng Liao,

Xinyu Wang

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Feb. 20, 2024

Abstract Melanoma is a malignant skin tumor. This study aimed to explore and assess the effect of novel biomarkers on progression melanoma. Differently expressed genes (DEGs) were screened from GSE3189 GSE46517 datasets Gene Expression Omnibus database using GEO2R. Ontology Kyoto Encyclopedia Genes Genomes pathway analyses conducted based identified DEGs. Hub assessed protein–protein interaction networks, principal component analysis, receiver operating characteristic curves. Quantitative real-time polymerase chain reaction was employed measure mRNA expression levels. TIMER revealed association between aldehyde dehydrogenase 2 (ALDH2) tumor immune microenvironment. The viability, proliferation, migration, invasion detected by cell counting kit-8, 5-ethynyl-2′-deoxyuridine, wound healing, transwell assays. Total 241 common DEGs out datasets. We determined 6 hub with high prediction values for melanoma, which could distinguish samples normal samples. ALDH2, ADH1B, ALDH3A2, DPT, EPHX2, GATM down-regulated in A375 SK-MEL-2 cells, compared human melanin line (PIG1 cells). ALDH2 selected as candidate gene this research, presenting diagnostic predictive value had positive correlation infiltrating levels cells melanoma Overexpression inhibited A375/SK-MEL-2 cells. new biomarker exerts an inhibitory

Language: Английский

Citations

4
YY1-induced lncRNA00511 promotes melanoma progression via the miR-150-5p/ADAM19 axis DOI Open Access

Ya-Ni Chen

American Journal of Cancer Research, Journal Year: 2024, Volume and Issue: 14(2), P. 809 - 831

Published: Jan. 1, 2024

Increasing evidence indicates that long noncoding RNAs (lncRNAs) are therapeutic targets and key regulators of tumors development progression, including melanoma.Long intergenic non-protein-coding RNA 511 (LINC00511) has been demonstrated as an oncogenic molecule in breast, stomach, colorectal, lung cancers.However, the precise role functional mechanisms LINC00511 melanoma remain unknown.This study confirmed was highly expressed cells (A375 SK-Mel-28 cells) tissues, knockdown could inhibit cell migration invasion, well growth subcutaneous tumor xenografts vivo.By using Chromatin immunoprecipitation (ChIP) assay, it transcription factor Yin Yang 1 (YY1) is capable binding to promoter enhancing its expression cis.Further mechanistic investigation showed mainly enriched cytoplasm interacted directly with microRNA-150-5p (miR-150-5p).Consistently, miR-150-5p recover effects on cells.Furthermore, ADAM metallopeptidase domain 19 (ADAM19) identified a downstream target miR-150-5p, overexpression ADAM19 promote proliferation.Rescue assays indicated acted competing endogenous (ceRNA) sponge increase ADAM19, thereby activating PI3K/AKT pathway.In summary, we lncRNA defined LINC00511/miR-150-5p/ADAM19 axis, which might be considered potential novel molecular mechanism treatment patients melanoma.

Language: Английский

Citations

3
Gasdermin E as a potential target and biomarker for CRISPR-Cas9-based cancer therapy DOI
Mojtaba Tarin, Amir Sh. Saljooghi

Biochemical Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 116961 - 116961

Published: April 1, 2025

Language: Английский

Citations

0
Unveiling the Dynamic Interplay between Cancer Stem Cells and the Tumor Microenvironment in Melanoma: Implications for Novel Therapeutic Strategies DOI Open Access
Patrízia Limonta, Raffaella Chiaramonte, Lavinia Casati

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(16), P. 2861 - 2861

Published: Aug. 16, 2024

Cutaneous melanoma still represents a significant health burden worldwide, being responsible for the majority of skin cancer deaths. Key advances in therapeutic strategies have significantly improved patient outcomes; however, most patients experience drug resistance and tumor relapse. Cancer stem cells (CSCs) are small subpopulation different tumors, including melanoma, endowed with distinctive capacities self-renewal differentiation into bulk cells. Melanoma CSCs characterized by expression specific biomarkers intracellular pathways; moreover, they play pivotal role onset, progression resistance. In recent years, great efforts been made to dissect molecular mechanisms underlying protumor activities provide basis novel CSC-targeted therapies. Herein, we highlight intricate crosstalk between bystander microenvironment (TME), immune cells, endothelial cancer-associated fibroblasts (CAFs), its progression. Specifically, discuss peculiar escape host surveillance, recruit immunosuppressive educate toward an phenotype. We also address currently investigated that could pave way new promising approaches care.

Language: Английский

Citations

2
YY1-induced lncRNA00511 promotes melanoma progression via the miR-150- 5p/ADAM19 axis DOI Creative Commons

yani Chen,

Xinrui Fu,

Hua Guo

et al.

Research Square (Research Square), Journal Year: 2023, Volume and Issue: unknown

Published: June 29, 2023

Abstract Background Long noncoding RNAs (lncRNAs) are key regulators of oncogenic processes, and one such lncRNA is lncRNA511 (LINC00511), which associated with breast, stomach, lung, colorectal cancers. However, its specific involvement in melanoma remains unclear. Here, we aimed to investigate the expression functional role LINC00511 melanoma. Methods We examined cell lines (A375 SK-Mel-28) tissues obtained from patients. conducted knockdown experiments assess effects on migration, invasion, tumor growth in vivo. To transcription regulators, performed chromatin immunoprecipitation assays. Additionally, analyzed subcellular localization confirmed that interaction microRNA-150-5p (miR-150-5p) by RNA assay (RIP), miRNA pull-down luciferase reporter assay. Furthermore, rescue assays validate our findings, namely LINC00511/miR-150-5p/ADAM19 axis impact PI3K/AKT pathway. Results was found be highly expressed patient tissues. Knockdown resulted inhibition subcutaneous Yin Yang 1 (YY1) identified as factor responsible for upregulation. predominantly localized cytoplasm exhibited direct miR-150-5p. miR-150-5p rescued silencing cells. Moreover, ADAM19 a downstream target miR-150-5p, overexpression promoted proliferation. Rescue acted competing endogenous RNA, sponging increasing expression, culminating activation Conclusion This study establishes an defines novel axis, represents promising therapeutic treatment. Further investigations targeting this hold potential improving outcomes

Language: Английский

Citations

2
Comparative genome-wide identification and characterization of SET domain-containing and JmjC domain-containing proteins in piroplasms DOI Creative Commons

Qindong Liang,

Shangdi Zhang,

Zeen Liu

et al.

BMC Genomics, Journal Year: 2024, Volume and Issue: 25(1)

Published: Aug. 26, 2024

SET domain-containing histone lysine methyltransferases (HKMTs) and JmjC demethylases (JHDMs) are essential for maintaining dynamic changes in methylation across parasite development infection. However, information on the HKMTs JHDMs human pathogenic piroplasms, such as Babesia duncani microti, veterinary important pathogens, including bigemina, bovis, Theileria annulata parva, is limited. A total of 38 putative KMTs eight were identified using a comparative genomics approach. Phylogenetic analysis revealed that can be divided into subgroups, while belong to JARID subfamily, except BdJmjC1 (BdWA1_000016) TpJmjC1 (Tp Muguga_02g00471) which cluster with domain only subfamily members. The motifs domains highly conserved among piroplasm species. Interspecies collinearity provided insight evolutionary duplication events some gene families. Moreover, relative expression by RT‒qPCR demonstrated KMT JHDM families differentially expressed different intraerythrocytic developmental stages B. duncani, suggesting their role Apicomplexa development. Our study provides theoretical foundation guidance understanding basic characteristics several biological roles differentiation.

Language: Английский

Citations

0
Advances in Tumor-Infiltrating Lymphocyte (TIL) as a Prognostic Factor and for Treating Invasive Cutaneous Melanoma DOI Open Access
Gabriel Alves Freiria de Oliveira, Daniel Arcuschin de Oliveira, Melissa Yoshimi Sakamoto Maeda Nisimoto

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(23), P. 12596 - 12596

Published: Nov. 23, 2024

Invasive cutaneous melanoma is responsible for about 5% of skin tumors yet liable nearly 70% cancer-related deaths. Despite notable advancements over the past decade, including immunotherapies and targeted treatments, more than half invasive patients ultimately succumb to disease due therapeutic resistance. To overcome this obstacle, strategies such as combining with drugs or adding epigenetic therapies have been investigated. Tumor-infiltrating lymphocytes (TILs) therapy has emerged a promising option whose continues progress despite standard treatments. This article aims introduce TIL review recent outcomes in prognosis its application management.

Language: Английский

Citations

0